Septerna (NASDAQ:SEPN) Insider Samira Shaikhly Sells 11,798 Shares

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the sale, the insider directly owned 793 shares in the company, valued at $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Samira Shaikhly also recently made the following trade(s):

• On Monday, March 2nd, Samira Shaikhly sold 70,453 shares of Septerna stock. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30.

Septerna Trading Up 4.2%

SEPN traded up $1.26 during trading on Thursday, reaching $31.05. 219,147 shares of the company’s stock were exchanged, compared to its average volume of 311,677. Septerna, Inc. has a one year low of $9.11 and a one year high of $32.63. The stock has a market capitalization of $1.40 billion, a PE ratio of -38.33 and a beta of 2.21. The firm has a fifty day moving average price of $25.24 and a two-hundred day moving average price of $25.98.

Septerna (NASDAQ:SEPN) last posted its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The firm had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. Sell-side analysts expect that Septerna, Inc. will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Septerna

Several hedge funds and other institutional investors have recently bought and sold shares of SEPN. Woodline Partners LP boosted its position in shares of Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after purchasing an additional 282,585 shares in the last quarter. Rhumbline Advisers increased its position in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after buying an additional 3,323 shares in the last quarter. Geode Capital Management LLC raised its stake in Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after buying an additional 78,316 shares during the period. JPMorgan Chase & Co. raised its stake in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after buying an additional 1,315 shares during the period. Finally, CW Advisors LLC bought a new position in Septerna in the second quarter worth approximately $133,000.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Tuesday, April 21st. JPMorgan Chase & Co. raised their price target on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Septerna in a research report on Wednesday, May 13th. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, Truist Financial increased their price objective on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.13.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.